{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:41:51Z","timestamp":1788327711859,"version":"build-2803163510"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>New treatments for advanced retinoblastoma (RB) have offered alternatives to primary enucleation. We assessed the impact of these therapies on the indications for enucleation and the histopathological findings in enucleated eyes with RB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>\n                      Eyes of all patients who underwent enucleation for RB at a single institution between January 2005 and August 2021 were included. Data collected retrospectively included demographics, clinical and pathologic staging, pathologic findings, and management. Statistical analysis included Kendall\u2019s \u03c4\n                      <jats:sub>b<\/jats:sub>\n                      , Pearson\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      , and Cram\u00e9r\u2019s V.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      There were 254 eyes from 252 patients with information available for review. Annual enucleations decreased between 2005 and 2008 at a rate of 4.2 enucleations\/year, increased from 2008 to 2013 at a rate of 2.7 enucleations\/year and decreased from 2013 to 2019 at a rate of 1.5 enucleations\/year, reflecting changes in RB therapies. When compared to earlier years, the eyes enucleated in recent years were more likely to be enucleated for patient symptoms (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and insufficient view (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.019), were more likely to have prior treatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), had lower tumor stage (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.010) and grade (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006), contained no viable tumor (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and were phthisical (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). Five of 252 patients (2%) developed metastases; one of these patients had no viable tumor in a previously treated enucleated eye.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Therapeutic innovations shifted the management of RB from primary enucleation in favor of eye salvage. Enucleated eyes show less viable tumor and disease severity but more intraocular degeneration, emphasizing the importance of skilled pathologic interpretation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tjo.tjo-d-24-00107","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T02:00:28Z","timestamp":1741312828000},"page":"88-102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Evolving trends in retinoblastoma management: A 16-year clinicopathological analysis of enucleated eyes"],"prefix":"10.4103","volume":"15","author":[{"given":"Ari H.","family":"August","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Department of Pathology, Wills Eye Hospital, Philadelphia, PA, USA"},{"name":"Department of Translational Ophthalmology, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy","family":"Curtis","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Department of Pathology, Wills Eye Hospital, Philadelphia, PA, USA"},{"name":"Department of Psychiatry, University of Maryland, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Eiger-Moscovich","sequence":"additional","affiliation":[{"name":"Department of Pathology, Wills Eye Hospital, Philadelphia, PA, USA"},{"name":"Department of Ophthalmology, Hadassah Medical Center, Jerusalem, Israel"},{"name":"Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Yaghy","sequence":"additional","affiliation":[{"name":"Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, USA"},{"name":"Department of Ophthalmology and Visual Sciences, UMass Chan Medical School, Worcester, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Lally","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph C","family":"Eagle","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Department of Pathology, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Milman","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Department of Pathology, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"R1-20250320","doi-asserted-by":"crossref","first-page":"962","DOI":"10.18240\/ijo.2023.06.20","article-title":"Epidemiological aspect of retinoblastoma in the world:A review of recent advance studies","volume":"16","author":"Koochakzadeh","year":"2023","journal-title":"Int J Ophthalmol"},{"key":"R2-20250320","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0161-6420(87)33407-4","article-title":"Historic review of retinoblastoma","volume":"94","author":"Albert","year":"1987","journal-title":"Ophthalmology"},{"key":"R3-20250320","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1167\/iovs.04-1462","article-title":"Retinoblastoma in the 20th century:Past success and future challenges the Weisenfeld lecture","volume":"46","author":"Abramson","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20250320","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajo.2014.07.025","article-title":"Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson memorial lecture","volume":"158","author":"Grossniklaus","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R5-20250320","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/ICU.0b013e328338676a","article-title":"Retinoblastoma management:Advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy","volume":"21","author":"Shields","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"R6-20250320","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/0002-9394(89)90116-5","article-title":"The role of cryotherapy in the management of retinoblastoma","volume":"108","author":"Shields","year":"1989","journal-title":"Am J Ophthalmol"},{"key":"R7-20250320","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/ICU.0b013e3283524130","article-title":"Intravenous and intra-arterial chemotherapy for retinoblastoma:What have we learned?","volume":"23","author":"Shields","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"R8-20250320","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.4103\/ijo.IJO_721_20","article-title":"Modern treatment of retinoblastoma:A 2020 review","volume":"68","author":"Ancona-Lezama","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R9-20250320","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/APO.0000000000000360","article-title":"Outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma based on patient age in 964 eyes of 554 patients","volume":"10","author":"Bas","year":"2021","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R10-20250320","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/s41388-017-0050-x","article-title":"The management of retinoblastoma","volume":"37","author":"Fabian","year":"2018","journal-title":"Oncogene"},{"key":"R11-20250320","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/eye.2012.175","article-title":"Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy","volume":"27","author":"Shields","year":"2013","journal-title":"Eye (Lond)"},{"key":"R12-20250320","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/ICU.0000000000000091","article-title":"Targeted retinoblastoma management:When to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy","volume":"25","author":"Shields","year":"2014","journal-title":"Curr Opin Ophthalmol"},{"key":"R13-20250320","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.21.02337","article-title":"Intensive multimodality therapy for extraocular retinoblastoma:A children's oncology group trial (ARET0321)","volume":"40","author":"Dunkel","year":"2022","journal-title":"J Clin Oncol"},{"key":"R14-20250320","doi-asserted-by":"crossref","first-page":"207","DOI":"10.17219\/acem\/166664","article-title":"A meta-analysis of the efficacy of intra-arterial chemotherapy for the management of retinoblastoma patients","volume":"33","author":"Yu","year":"2024","journal-title":"Adv Clin Exp Med"},{"key":"R15-20250320","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/neurintsurg-2019-014909","article-title":"Intra-arterial chemotherapy for retinoblastoma:An updated systematic review and meta-analysis","volume":"11","author":"Ravindran","year":"2019","journal-title":"J Neurointerv Surg"},{"key":"R16-20250320","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000491432","article-title":"Precision intravitreal chemotherapy for localized vitreous seeding of retinoblastoma","volume":"5","author":"Yu","year":"2019","journal-title":"Ocul Oncol Pathol"},{"key":"R17-20250320","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/jamaophthalmol.2015.3108","article-title":"Treatment of retinoblastoma in 2015:Agreement and disagreement","volume":"133","author":"Abramson","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R18-20250320","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamaophthalmol.2013.7666","article-title":"Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds:Preliminary results","volume":"132","author":"Shields","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R19-20250320","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/IAE.0000000000000903","article-title":"Intravitreous chemotherapy for active vitreous seeding from retinoblastoma:Outcomes after 192 consecutive injections. The 2015 Howard Naquin lecture","volume":"36","author":"Shields","year":"2016","journal-title":"Retina"},{"key":"R20-20250320","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/bjo-2022-322492","article-title":"Ten-year experience with intracameral chemotherapy for aqueous seeding in retinoblastoma:Long-term efficacy, safety and toxicity","volume":"108","author":"Stathopoulos","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"R21-20250320","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamaoncol.2019.6716","article-title":"Global retinoblastoma presentation and analysis by national income level","volume":"6","author":"Fabian","year":"2020","journal-title":"JAMA Oncol"},{"key":"R22-20250320","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ophtha.2014.11.029","article-title":"Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma","volume":"122","author":"Francis","year":"2015","journal-title":"Ophthalmology"},{"key":"R23-20250320","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/neurintsurg-2020-016759","article-title":"Incidence and predictors of ophthalmic artery occlusion in intra-arterial chemotherapy for retinoblastoma","volume":"13","author":"Sweid","year":"2021","journal-title":"J Neurointerv Surg"},{"key":"R24-20250320","first-page":"577","article-title":"Complications of systemic chemotherapy as treatment of retinoblastoma","volume":"118","author":"Benz","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R25-20250320","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.ophtha.2006.06.018","article-title":"The international classification of retinoblastoma predicts chemoreduction success","volume":"113","author":"Shields","year":"2006","journal-title":"Ophthalmology"},{"key":"R28-20250320","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000530730","article-title":"The 5th edition of the World Health Organization classification of tumours of the eye and orbit","volume":"9","author":"Milman","year":"2023","journal-title":"Ocul Oncol Pathol"},{"key":"R29-20250320","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/archophthalmol.2011.223","article-title":"Histopathologic observations after intra-arterial chemotherapy for retinoblastoma","volume":"129","author":"Eagle","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R30-20250320","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaophthalmol.2021.4732","article-title":"Defining high-risk retinoblastoma:A multicenter global survey","volume":"140","author":"Kaliki","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R31-20250320","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ophtha.2012.10.044","article-title":"High-risk retinoblastoma based on international classification of retinoblastoma:Analysis of 519 enucleated eyes","volume":"120","author":"Kaliki","year":"2013","journal-title":"Ophthalmology"},{"key":"R32-20250320","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.5858\/133.8.1203","article-title":"High-risk features and tumor differentiation in retinoblastoma:A retrospective histopathologic study","volume":"133","author":"Eagle","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"R33-20250320","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.ophtha.2017.04.015","article-title":"Vitreous seeds in retinoblastoma:Clinicopathologic classification and correlation","volume":"124","author":"Amram","year":"2017","journal-title":"Ophthalmology"},{"key":"R35-20250320","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ophtha.2022.04.006","article-title":"High-risk pathologic features based on presenting findings in advanced intraocular retinoblastoma:A multicenter, international data-sharing American Joint Committee on Cancer Study","volume":"129","author":"Tomar","year":"2022","journal-title":"Ophthalmology"},{"key":"R36-20250320","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1200\/JCO.18.01808","article-title":"Study of unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy:A children's oncology group study","volume":"37","author":"Ch\u00e9vez-Barrios","year":"2019","journal-title":"J Clin Oncol"},{"key":"R37-20250320","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10260-010-0142-z","article-title":"Influence functions of the spearman and Kendall correlation measures","volume":"19","author":"Croux","year":"2010","journal-title":"Stat Methods Appt"},{"key":"R38-20250320","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/biomet\/30.1-2.81","article-title":"A new measure of rank correlation","volume":"30","author":"Kendall","year":"1938","journal-title":"Biometrika"},{"key":"R39-20250320","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.4103\/ijo.IJO_2243_21","article-title":"Impact of COVID-19 nationwide lockdown on retinoblastoma treatment and outcome:A study of 476 eyes of 326 children","volume":"69","author":"Bansal","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R40-20250320","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.3390\/jcm10225421","article-title":"Changes in treatment patterns and globe salvage rate of advanced retinoblastoma in Korea:Efficacy of intra-arterial chemotherapy","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med"},{"key":"R41-20250320","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archophthalmol.2011.150","article-title":"Intra-arterial chemotherapy for retinoblastoma:Report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds","volume":"129","author":"Shields","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R42-20250320","doi-asserted-by":"crossref","first-page":"e0145436","DOI":"10.1371\/journal.pone.0145436","article-title":"Advanced unilateral retinoblastoma:The impact of ophthalmic artery chemosurgery on enucleation rate and patient survival at MSKCC","volume":"10","author":"Abramson","year":"2015","journal-title":"PLoS One"},{"key":"R43-20250320","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3928\/0191-3913-20030701-05","article-title":"Trends in the management of retinoblastoma:Evaluation of 1,196 consecutive eyes during 1974 to 2001","volume":"40","author":"Epstein","year":"2003","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R44-20250320","doi-asserted-by":"crossref","first-page":"696787","DOI":"10.3389\/fphar.2021.696787","article-title":"Safety and efficacy of intravitreal chemotherapy (melphalan) to treat vitreous seeds in retinoblastoma","volume":"12","author":"Yousef","year":"2021","journal-title":"Front Pharmacol"},{"key":"R45-20250320","doi-asserted-by":"crossref","first-page":"338.e1","DOI":"10.1016\/j.jaapos.2023.08.013","article-title":"Direct medical costs of globe salvage in group C-E retinoblastoma and implications for cost-effectiveness","volume":"27","author":"Zhang","year":"2023","journal-title":"J AAPOS"},{"key":"R46-20250320","doi-asserted-by":"crossref","first-page":"e13209","DOI":"10.1111\/ecc.13209","article-title":"Childhood eye cancer from a parental perspective:The lived experience of parents with children who have had retinoblastoma","volume":"29","author":"Beddard","year":"2020","journal-title":"Eur J Cancer Care (Engl)"},{"key":"R47-20250320","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1017\/S1478951519000920","article-title":"Impact of enucleation on adult retinoblastoma survivors'quality of life:A qualitative study of survivors'perspectives","volume":"18","author":"Banerjee","year":"2020","journal-title":"Palliat Support Care"},{"key":"R48-20250320","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ophtha.2022.04.022","article-title":"Metastatic death based on presenting features and treatment for advanced intraocular retinoblastoma:A multicenter registry-based study","volume":"129","author":"Tomar","year":"2022","journal-title":"Ophthalmology"},{"key":"R49-20250320","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1002\/cam4.5406","article-title":"Survival trends for patients with retinoblastoma between 2000 and 2018: What has changed?","volume":"12","author":"Abdelazeem","year":"2023","journal-title":"Cancer Med"},{"key":"R50-20250320","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2010.32.5332","article-title":"Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis","volume":"29","author":"Zhao","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-24-00107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:51:41Z","timestamp":1786647101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-24-00107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-24-00107","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-09-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}